Welcome to our dedicated page for Longevity Health SEC filings (Ticker: XAGEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Longevity Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Longevity Health's regulatory disclosures and financial reporting.
Key update: Longevity Health Holdings, Inc. (trading symbols: XAGE common shares, XAGEW warrants) filed an 8-K on 24 June 2025 announcing Amendment No. 1 to its 11 April 2025 Agreement and Plan of Merger with 20/20 Biolabs, Inc. and related parties.
Amendment terms:
- The Due Diligence Contingency Deadline is postponed from 24 June 2025 to 8 July 2025.
- If the parties do not mutually agree to another extension in writing, the entire Merger Agreement will automatically terminate on 8 July 2025.
- No other economic terms, consideration mix, or exchange ratios were modified in the filing.
Strategic context: The proposed transaction would merge Longevity Health Biomarkers, Inc. (a wholly-owned subsidiary of Longevity Health Holdings) with Biolabs, making Biolabs a wholly-owned subsidiary of the registrant. Management reiterates typical forward-looking-statement caveats and highlights numerous risks—chiefly regulatory approvals, integration challenges, Nasdaq listing maintenance, financing completion and possible cost overruns.
Investor implications:
- The short two-week extension suggests that due-diligence issues remain open but that the parties still aim to close quickly.
- Automatic termination language increases deal-completion risk and introduces a hard stop date that investors should monitor closely.
- No financial statements, pro forma data, or revised purchase price details were provided; therefore, the amendment’s direct quantitative impact cannot yet be assessed.
- The company remains an emerging growth company and smaller reporting company, so reduced disclosure requirements apply.
Overall, the filing is limited to extending a key deadline. While it keeps the deal alive, it also underscores continued uncertainties that could materially influence Longevity Health’s strategy, valuation and warrant pricing.
Longevity Health Holdings (Nasdaq: XAGE; warrants: XAGEW) filed a Form 8-K announcing Amendment No. 1 to its April 11 2025 Merger Agreement with 20/20 Biolabs.
- The amendment extends the Due Diligence Contingency Deadline to July 8 2025.
- If not further extended, the agreement will automatically terminate on July 8 2025.
- No other economic or structural terms were changed; Biolabs would become a wholly-owned subsidiary upon closing.
- Filed under Item 1.01; full text appears as Exhibit 2.1.
The report contains extensive forward-looking statements on regulatory approvals, integration, Nasdaq compliance and cost risks. Investors should watch for additional filings before the new deadline.
FAQ
What is the current stock price of Longevity Health (XAGEW)?
